JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M401089200 on April 1, 2004

J. Biol. Chem., Vol. 279, Issue 24, 25789-25797, June 11, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/24/25789    most recent
M401089200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edavettal, S. C.
Right arrow Articles by Pedersen, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edavettal, S. C.
Right arrow Articles by Pedersen, L. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Crystal Structure and Mutational Analysis of Heparan Sulfate 3-O-Sulfotransferase Isoform 1*

Suzanne C. Edavettal{ddagger}, Karen A. Lee§, Masahiko Negishi¶, Robert J. Linhardt||, Jian Liu{ddagger}**, and Lars C. Pedersen§

From the {ddagger}Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, §Laboratory of Structural Biology and Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, and ||Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, New York 12180

Received for publication, January 30, 2004 , and in revised form, March 10, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Heparan sulfate interacts with antithrombin, a protease inhibitor, to regulate blood coagulation. Heparan sulfate 3-O-sulfotransferase isoform 1 performs the crucial last step modification in the biosynthesis of anticoagulant heparan sulfate. This enzyme transfers the sulfuryl group (SO3) from 3'-phosphoadenosine 5'-phosphosulfate to the 3-OH position of a glucosamine residue to form the 3-O-sulfo glucosamine, a structural motif critical for binding of heparan sulfate to antithrombin. In this study, we report the crystal structure of 3-O-sulfotransferase isoform 1 at 2.5-Å resolution in a binary complex with 3'-phosphoadenosine 5'-phosphate. This structure reveals residues critical for 3'-phosphoadenosine 5'-phosphosulfate binding and suggests residues required for the binding of heparan sulfate. In addition, site-directed mutagenesis analyses suggest that residues Arg-67, Lys-68, Arg-72, Glu-90, His-92, Asp-95, Lys-123, and Arg-276 are essential for enzymatic activity. Among these essential amino acid residues, we find that residues Arg-67, Arg-72, His-92, and Asp-95 are conserved in heparan sulfate 3-O-sulfotransferases but not in heparan N-deacetylase/N-sulfotransferase, suggesting a role for these residues in conferring substrate specificity. Results from this study provide information essential for understanding the biosynthesis of anticoagulant heparan sulfate and the general mechanism of action of heparan sulfate sulfotransferases.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Heparan sulfate (HS)1 is widely expressed in animal and human tissues. It has diverse roles in development, assisting viral infections, and homeostasis (1-3). HS is a highly sulfated polysaccharide consisting of 1-4-linked sulfated glucosamine and sulfated glucuronic/iduronic acid residues. The specific sequences of sulfated saccharide in HS determine its various functions.

Synthesis of biologically active HS is accomplished through a complex biosynthetic pathway. HS is initially synthesized as a copolymer of glucuronic acid and N-acetylated glucosamine by D-glucuronyl and N-acetyl-D-glucosaminyltransferase followed by various modifications in the Golgi apparatus (4). These modifications include N-deacetylation and N-sulfonation of glucosamine, C5 epimerization of glucuronic acid to form iduronic acid residues, and 2-O-sulfonation of iduronic and glucuronic acid residues as well as 6-O-sulfonation and 3-O-sulfonation of the glucosamine units. The stepwise sulfonation reactions are illustrated in Fig. 1. All of the enzymes that are responsible for the biosynthesis of HS have been cloned and characterized (5).



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 1.
The schematic biosynthesis of anticoagulant heparan sulfate. Five steps are involved in the biosynthesis of HS after the polysaccharide backbone is made. The numbers indicate the positions of each sugar unit. Both N-deacetylase/N-sulfotransferase and C5-epimerase modifications are indicated in red. The 2-O-sulfotransferase and 6-O-sulfotransferase modifications are indicated in black and blue, respectively. The 3-O-sulfotransferase modification is indicated in purple. For clarity, we have indicated the 3-O-sulfotransferase isoform 1 modifications only in this figure. GlcUA, glucuronic; IdoUA, iduronic acid; Glc, glucosamine.

 
The blood coagulation pathway is composed of a cascade of proteolytic reactions ultimately generating fibrin thrombi. The proanticoagulant activity of this cascade is balanced by several natural anticoagulant mechanisms. Binding of HS to antithrombin (AT) represents the most important of these mechanisms. HS achieves its anticoagulant activity by interacting with AT, which undergoes a conformation change, generating the active form of AT to inhibit blood coagulation factors Xa and thrombin. This anticoagulant process prevents the formation of deleterious blood clots. Heparin, a specialized HS found in mast cells, is the most commonly used anticoagulant drug.

Anticoagulant HS and heparin contain structurally defined AT binding pentasaccharide sequences with the structure, -GlcNS(or Ac)6S-GlcUA-GlcNS3S±6S-IdoUA2S-GlcNS6S- (GlcUA is glucuronic, and IdoUA is iduronic acid) (Fig. 1) (6). The 3-O-sulfo glucosamine unit (GlcNS3S±6S) in this binding site is essential for interaction with AT. The lack of a 3-O-sulfo group in this unit decreases AT binding affinity by 18,000-fold (6). A recently approved anticoagulant drug, Arixtra, prepared by organic synthesis is based on this pentasaccharide scaffold. The recently reported enzymatic synthesis of a similar pentasaccharide utilizes 3-OST-1 in the last modification step (5) and opens up a new approach to preparation of such anticoagulants.

The essential physiological role of 3-O-sulfo HS (or anticoagulant HS) in blood coagulation is best demonstrated through the study of AT and AT mutants. A severe thrombosis phenotype is observed in mice carrying an AT mutant defective in heparin binding, suggesting a key role for HS-AT interaction in balancing procoagulant and anticoagulant activities in vivo (7). Additionally, patients with AT mutants defective in heparin and HS binding suffer from thrombosis (8-10). Furthermore, it appears that complete ablation of AT-HS binding is required to reveal the full physiological role of anticoagulant HS in vivo (11). The final step in the biosynthesis of anticoagulant HS can be catalyzed by either 3-OST-1 or 3-OST-5 isoforms (12, 13). Gene redundancy in the biosynthesis of anticoagulant HS helps to explain why 3-OST-1 knockout mice failed to exhibit a prothrombotic phenotype (14).

Heparan sulfate 3-O-sulfotransferase (3-OST) is present in at least six different isoforms that have unique expression patterns in human tissues (15, 16). The amino acid sequences of the different isoforms have 50-80% homology in their sulfotransferase domains (15). These different 3-OST isoforms transfer sulfuryl groups to the 3-OH position of glucosamine units residing within the context of different saccharide sequences. As a result, the HS products generated by these different isoforms exhibit unique and distinctive biological activities. It is known that HS modified by 3-OST-1 and 3-OST-5 display anticoagulant activity, whereas HS modified by 3-OST-3 and 3-OST-5 serve as entry receptors for herpes simplex virus-1 (12, 16, 17). The structural features of 3-OST isoforms that dictate substrate specificity are currently unknown.

The sulfotransferase family can be organized into two categories based on the sub-cellular localizations; they are cytosolic and Golgi sulfotransferases (18, 19). The crystal structures of different sulfotransferases reveal structural similarity in their PAPS binding sites between the cytosolic and Golgi sulfotransferases, suggesting that different sulfotransferases probably follow similar mechanisms in the transfer of the sulfuryl group even though they exhibit high selectivity in substrate binding (20, 21). The structures of a number of cytosolic sulfotransferases complexed with acceptor substrates have been solved, providing clues that have led to a better understanding of their catalytic mechanism and mode of substrate recognition (22-24). HS sulfotransferases are considered to be Golgi sulfotransferases. The crystal structure of the binary complex of the sulfotransferase domain of the HS N-deacetylase/N-sulfotransferase (NST-1) and 3'-phosphoadenosine 5'-phosphate (PAP) was solved by Kakuta et al. (21). This represents the first and only structure of a HS sulfotransferase previously determined.

In this study, we report the crystal structure of a binary complex of mouse 3-OST-1 and PAP. The structure of this enzyme is very similar to NST-1 but with unique structural features in the HS binding cleft. Results from mutational analysis of amino acid residues at and around the active site in 3-OST-1 reveal a series of amino acid residues that is critical for sulfotransferase activity. These results, when combined with a structural alignment to NST-1 and sequence alignments to other isoforms of 3-OST, provide insight into the role certain residues may play in catalysis and dictating substrate specificity for these HS sulfotransferases.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Materials—Full-length mouse 3-OST-1 cDNA (m3-OST-1-pcDNA3) was purified from a mouse L-cell cDNA library (25). [35S]PAPS was prepared by incubating 0.4-2 mCi/ml [35S]Na2SO4 (carrier-free, MP Biomedical) and 16 mM ATP with 5 mg/ml dialyzed yeast extract (Sigma) (26). HS from bovine kidney was purchased from MP Biomedical (Irvine, CA). PAP was purchased from Sigma.

Expression, Purification, and Crystallization of 3-OST-1
Preparation of 3-OST-1 Bacterial Expression Plasmid (b3-OST-1-pET28)—The cDNA fragment encoding the catalytic domain of 3-OST-1 (G48-H311) was amplified from m3-OST-1-pcDNA3 with a 5' overhang containing an NdeI site and a 3' overhang containing an EcoRI site. This construct was inserted into the pET28a vector (Novagen) using the NdeI and EcoRI restriction sites to produce a His6-tagged protein. The resultant plasmid (b3-OST-1-pET28) was sequenced to confirm the reading frame and the lack of mutations within the coding region (University of North Carolina, DNA sequencing core facility). The plasmid, b3-OST-1-pET28, was transformed into BL21(DE3)RIL cells (Stratagene) for the expression of 3-OST-1.

Protein Expression and Purification—Cells containing the b3-OST-1-pET28 were grown in 12 2.8-liter Fernbach flasks containing 1 liter of LB media with 50 µg/ml kanamycin at 37 °C. When the A600 reached 0.6-0.8, the temperature was lowered to 22 °C for 15 min. Isopropyl-{beta}-D-thiogalactopyranoside was then added to a final concentration of 200 µM, and the cells were allowed to shake overnight. Cells were pelleted and resuspended in 120 ml of sonication buffer, 25 mM Tris, pH 7.5, 500 mM NaCl, and 10 mM imidazole. Cells were disrupted by sonication then spun down. The supernatant was applied to nickel nitrilotriacetic acid-agarose resin (Qiagen) in batch and washed with sonication buffer. The resin was loaded onto a column, and the protein was eluted with an imidazole gradient from 10 to 250 mM. The protein was dialyzed then concentrated to 16 mg/ml in 20 mM Tris, pH 7.5, 100 mM NaCl, and 4 mM PAP. A total of 28 mg of protein was obtained.

Protein Crystallization and Structure Solution—Crystals of 3-OST-1 were grown using the hanging drop method at 4 °C by mixing 2 µl of the protein solution with 2 µl of the reservoir solution containing 0.1 M citrate, pH 5.5, and 11% polyethylene glycol 4000. Before data collection, crystals were transferred to a solution containing 0.1 M citrate, pH 5.5, 20% polyethylene glycol 4000, 0.1 M NaCl, 4 mM PAP, and 12.5% ethylene glycol. The crystals were mounted in a loop and flash-frozen in liquid nitrogen. Data were collected at -180 °C on a RaxisIV area detector for the low resolution data set. A high resolution data set was collected on another crystal at the Advanced Photon Source on SERCAT beamline 22 using a MAR225 area detector. Both data sets were processed using HKL2000 (Table I) (27). A model of NST-1 (21) consisting of residues 603-632, 642-664, 670-736, 744-868, and PAP was used as a search molecule for molecular replacement using Molrep in CCP4 with the low resolution data set (28, 29). The positions of two (A and B) of the three final molecules in the asymmetric unit were found by molecular replacement. These two molecules were refined in CNS (30) and improved by iterative cycles of model building in O (31) and refinement in CNS until an Rfree value of 35% was obtained. At this point, sparse electron density became visible for the third molecule (C). A copy of molecule A was manually inserted into the density and refined. Density for molecule C was very poor, and the B-factors were very high, so refinement was carried out using non-crystallographic restraints between the third molecule and the first molecule. Residues for molecule C, which contained no electron density, were deleted. Refinement of molecule C dropped the Rfree to 31%. The final model was obtained by iterative cycles of model building and refinement of the three molecules against the high resolution data set. The final molecule contains residues 54-311 for molecule A and B and 54-269 and 281-311 for molecule C.


View this table:
[in this window]
[in a new window]
  		TABLE I
Crystallographic data statistics

 
Mutational Analysis of 3-OST-1
Preparation of 3-OST-1 Mutant Plasmids—A total of 28 point mutants of 3-OST-1 were prepared using b3-OST-1-pET28 as the template and the Gene Tailor site-directed mutagenesis kit from Invitrogen. The lengths and sequences of the primers for preparation of those mutants were designed based on the manufacturer's protocol for this mutagenesis kit and were synthesized by Invitrogen. The resultant constructs were sequenced to confirm the anticipated mutation (University of North Carolina, DNA sequencing core facility).

Expression and Purification of 3-OST-1 Mutants—The expression plasmids for various 3-OST-1 mutants were transformed individually into BL21(DE3)RIL cells (Stratagene). Each mutant construct was grown in 100 ml of LB broth and induced by isopropyl-{beta}-D-thiogalactopyranoside as described above. The bacteria cells were harvested and solubilized in sonication buffer before sonication. The lysate was subjected to a 400-µl nickel nitrilotriacetic acid-agarose column (0.75 x 1 cm) followed by a 5-ml of wash with sonication buffer. Mutant proteins were eluted with 1 ml of elution buffer containing 25 mM Tris, 500 mM NaCl, and 250 mM imidazole, pH 7.5. Approximately 25 µl of the eluent was subjected to the analysis on a 16.5% Tris-Tricine PAGE gel (Bio-Rad), and the gel was stained by Coomassie Blue. The expression level of the mutant protein was estimated by determining the intensity of the Coomassie-stained protein band near 30 kDa. As a positive control, we expressed wild type 3-OST-1 (b3-OST-1-pET28) along with the mutants. The expression levels and the sulfotransferase activity of mutant proteins were normalized to those of wild type protein.

Several clones harboring mutant proteins, including R67E, K68A, R72E, E90Q, K123A, and R276A, were grown in 2-4-liter cultures to obtain sufficient amounts of protein for analysis by isothermal titration calorimetry (ITC). Procedures for expression and purification of these mutants were essentially identical to those for the wild type 3-OST-1. Mutant protein was purified by nickel nitrilotriacetic acid-agarose chromatography, and purity was estimated to be greater than 80% by a 16.5% Tris-Tricine PAGE gel.

Determination of the Sulfotransferase Activity—Sulfotransferase activity was determined by incubating ~5 µl (10-100 ng) of purified mutant or wild type 3-OST-1 proteins with 10 µg of HS (from bovine kidney, ICN) and 5-10 x 104 cpm of [35S]PAPS (~10 µM) in 50 µl of buffer containing 50 mM MOPS, pH 7.0, 10 mM MnCl2,5mM MgCl2, and 1% Triton X-100. The reaction was incubated at 37 °C for 30 min and quenched by the addition of 6 M urea and 100 mM EDTA. The sample was then subjected to a 200-µl DEAE-Sepharose chromatography to purify the [35S]HS. The quantity of [35S]HS was then determined by liquid scintillation counting. The negative control contained all the components with the exception of 3-OST-1 proteins.

Determination of the Binding of AT and 3-O-Sulfated HS—Approximately 5 x 106 cpm of [35S]HS was incubated with 5 µg of human AT (Cutter Biological) in 50 µl of reaction buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100 for 30 min at room temperature. 60 µl of 1:1 slurry of pretreated concanavalin A-Sepharose (from Sigma) was added, and the reaction was agitated for 1 h at room temperature on an orbital shaker. The gel was washed three times with the buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM dextran sulfate, 0.02% sodium azide, and 0.0004% Triton X-100, and the bound [35S]HS was eluted with the same buffer containing 1000 mM NaCl.

ITC—ITC was performed on a MicroCal VP-ITC. Solutions were cooled to 10 °C and degassed under vacuum before use. Experiments were conducted using 17-21 µM protein in 100 mM phosphate buffer, pH 7.0) and 100 mM NaCl at 10 °C. Titrations were performed by injecting 5 µl of 4 mM PAP in 100 mM phosphate buffer, pH 7.0, and 100 mM NaCl. Data analysis was completed using Origin software.

Determination of PAP Binding Affinity Using PAP Chromatography—To determine the binding affinity of the wild type and mutant proteins to PAP, 3',5'-ADP-agarose chromatography (Sigma) was used. Approximately 200 µg of proteins, including wild type 3-OST-1, K68A, H92F, and D95N and R276A, in 5 ml of a buffer containing 25 mM Tris, pH 7.0, and 100 mM NaCl was loaded onto a 3',5'-ADP-agarose column (7 x 52 mm) pre-equilibrated with 25 mM Tris, pH 7.0, and 100 mM NaCl at a flow rate of 0.5 ml/min. Unbound material was removed by washing with 5 ml of 25 mM Tris, pH 7.0, and 100 mM NaCl. Bound proteins were eluted with a linear gradient of NaCl from 100 mM to 1 M in 10 ml. The samples from the collected fractions were analyzed by SDS-PAGE followed by staining with Coomassie Blue.


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Overall Fold—The catalytic domain of mouse 3-OST-1 (G48-H311) was successfully expressed in Escherichia coli. The catalytic domain has higher solubility than the full-length protein, making it more amenable to crystallization. The 3-OST-1 protein crystallized in the space group I4122 with 3 protein molecules (A, B, and C) in the asymmetric unit. Each molecule of 3-OST-1 contains one molecule of PAP bound. Two of the protein molecules (A and B) in the asymmetric unit stack together, forming hollow channels with the long dimension running parallel to the c axis of the unit cell. The rim of the channel is composed of 4 molecules of both A and B. The hollow inner solvent channel has a diameter of ~62 Å. The third molecule (C) is involved in cross-linking these channels by interacting with molecules B and a molecule C coming from another channel. This packing arrangement creates a cell with an overall solvent content of 76% and a Matthews coefficient of 5.5 (32). Molecules A and B are well ordered and have similar overall B-factors (Table I). Molecule C, however, is highly disordered, with overall B-factors ~2.5 times greater than molecules A and B, suggesting it may bind in slightly different orientations or have only partial occupancy in the crystal lattice. Because molecule C is highly disordered, the discussion of the structure will focus on molecules A and B.

The crystal structure of the 3-OST-1·PAP complex (Fig. 2a)is roughly spherical and contains a large open cleft. The structure is centered around an {alpha}/{beta} motif common to all sulfotransferases (18). This motif consists of a five-stranded parallel {beta}-sheet flanked on both sides by {alpha} helices. At the heart of the fold is a strand-loop-helix motif (Thr-61-Ser-79) consisting of the first {beta}-strand (The-61-Ile-64) and the first {alpha}-helix (Thr-71-Ser-79), which contains the phosphosulfate binding (PSB) loop (Gly-65-Gly-70) (22). This loop is very similar in structure to the P-loop found in protein kinases and forms extensive interactions with the 5'-phosphate of the PAP (Fig. 2b). As in other sulfotransferases, the helix that runs across the top of the PAP binding pocket and into the open cleft is also present. The C-terminal portion of the enzyme consists of a short three-stranded anti-parallel {beta}-sheet. Strands 2 and 3 of this sheet are stabilized by a disulfide bond (Cys-260-Cys-269). A coil consisting of residues 270-281 connects this sheet to the C-terminal helix. This coil practically buries the PAP molecule in the active site and may be susceptible to a conformational change since it is ordered in molecules A and B and there is no electron density visible for it in molecule C.



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 2.
The crystal structure of 3-OST-1 in complex with PAP. a, stereo ribbon diagram of the crystal structure of 3-OST-1. Also pictured is the donor product PAP and conserved residues Ser-159 and Lys-68 that interact with the 3'- and 5'-phosphates of PAP, respectively, as well as residue Glu-90, which has been proposed to be involved in catalysis. b, stereo diagram of the PAPS binding site of 3-OST-1 with PAP bound. The electron density for PAP from a simulated annealing omit map is drawn contoured at 8{sigma} (blue). Superimposed onto the active site are PAPS (pink) from the crystal structure of human estrogen sulfotransferase (PDB code1HY3) and 17{beta}-estradiol, the acceptor substrate, and the catalytic base His-108 (purple) from mouse estrogen sulfotransferase (PDB code 1AQU [PDB] ). Superpositions are based on the PSB loop of these structures. These superpositions suggest the position of the sulfuryl group of PAPS in 3-OST-1 binding as well as the position of the acceptor hydroxyl of the heparan substrate (the 3-hydroxyl on 17{beta}-estradiol). Hydrogen bonds between 3-OST-1 and PAP are drawn in dashed black lines as well as the interaction between His-108 and 17{beta}-estradiol in mouse estrogen sulfotransferase. Potential hydrogen bonds between 3-OST-1 residues and the sulfuryl group of PAPS are shown in dashed orange lines as is the potential interaction between Glu-90 and the acceptor hydroxyl of the substrate. The solid orange line (labeled with an asterisk) displays the direction of attack of the acceptor hydroxyl on the sulfuryl group for the proposed in-line transfer reaction mechanism. For this figure the oxygen, nitrogen, and phosphorous atoms are colored red, blue, and magenta, respectively. This figure was created using Molscript (37) and Raster3D (38).

 
The overall fold of 3-OST-1 is most similar to that of the sulfotransferase domain of NST-1 (21) (Fig. 3a). The root mean square of 230 structurally equivalent C{alpha}s is 1.3 Å, as determined by the program O (31). All of the significant secondary structural features are conserved between the two enzymes. The major differences occur in the loop regions as described below.



View larger version (57K):
[in this window]
[in a new window]
  		FIG. 3.
The superimposed structures of NST-1 and 3-OST-1. a, stereo diagram of the C{alpha} trace of the crystal structures of 3-OST-1 (green, PAP is in orange) with the sulfotransferase domain of NST-1 (pink) (PDB code 1NST [PDB] ). This figure clearly shows the large open cleft of the proposed heparan binding site. b, stereo diagram of the superposition of the active sites of 3-OST-1 and NST-1. Although the overall fold is similar, residues lining the cleft are quite different. In both panels a and b the loop unique to NST from residues 633 to 641 is colored blue. Glu-641 is labeled for clarity. For this figure the oxygen, nitrogen, and phosphorous atoms are colored red, blue, and magenta, respectively. This figure was created using Molscript (37) and Raster3D (38).

 
PAP Binding Site—A number of hydrogen-bonding interactions are involved in positioning the PAP molecule within the active site (Fig. 2b). Side chains from residues Lys-68 and Thr-71 of the PSB loop and Lys-274 of the coil that buries the PAP both form interactions with the 5'-phosphate (Table II). In addition, backbone amide nitrogens from the PSB loop (Gly-70, Thr-71, and Arg-72) are also within hydrogen-bonding distance of the 5'-phosphate. Although there are no protein interactions with the ribose ring, atom N6 of the adenosine base is within hydrogen-bonding distance to the carbonyl oxygen of Tyr-259. In addition, residues Phe-258, Ile-225, Ala-73, and Leu-270 are all within 4 Å of the base and assist in positioning the base through van der Waals forces.


View this table:
[in this window]
[in a new window]
  		TABLE II
Distance between PAP and free to 3-OST-1 residues

All distances are based on PAP bound to molecule B. The His-278 interaction does not exist in molecule A.

 
Like the 5'-phosphate binding site, the 3'-phosphate also forms a number of interactions with the protein. The side chain of Arg-151 is within hydrogen-bonding distance to the bridging O3 oxygen. In addition, the side chain oxygen of Ser-159 also lies within hydrogen-bonding distance of Arg-151 as well as with a 3'-phosphate oxygen. Backbone amides from residues Gly-275 and Arg-276 of the flexible loop also form interactions with the phosphate. In molecule B, atom NE2 of the side chain from His-278 is within hydrogen-bonding distance of the phosphate as well; however, this residue has a different conformation in molecule A and consequently is not near the phosphate.

Catalytic Mechanism—Heparan sulfotransferases, including 3-OST-1 and NST-1, and cytosolic sulfotransferases recognize substrates that have distinct chemical structures. Based on structural similarities and utilization of the same sulfuryl donor, PAPS, it is believed that heparan sulfotransferases and cytosolic sulfotransferases share a common mechanism (33). Superposition of 3-OST-1 with structures of estrogen sulfotransferase, a representative cytosolic sulfotransferase, with PAPS and 17{beta}-estradiol bound depicts the catalytic functions of the key amino acid residues for the activities of 3-OST-1 and estrogen sulfotransferase (Fig. 2b). The mechanism of the cytosolic sulfotransferases has been suggested to proceed through an SN2-like in-line displacement mechanism whereby the acceptor hydroxyl acts as a nucleophile, which when deprotonated by a conserved histidine attacks the sulfur atom of PAPS (20, 22). This creates a trigonal bi-pyramidal transition state with the PAP and acceptor group in the axial positions. The negative charge build up on the leaving PAP group is stabilized by a conserved lysine residue on the PSB loop that forms a hydrogen bond with the bridging oxygen to the sulfur atom. This lysine is in a similar conformation in both the structures of estrogen sulfotransferase in complex with PAP and 17{beta}-estradiol and 3-OST-1 in complex with PAP. Interestingly, in the estrogen sulfotransferase-PAPS binary complex, the lysine lies in a different conformation and forms a hydrogen bond with a conserved serine that also forms hydrogen bonds with the 3'-phosphate of PAP (24). This interaction may be essential for all sulfotransferases to reduce the rate of hydrolysis of PAPS in the absence of acceptor substrate.

The lysine and serine residues, which are used by estrogen sulfotransferase to position and stabilize PAPS, are conserved in NST-1 (Lys-614, Ser-712) as well as in the 3-OSTs including 3-OST-1 (Lys-68, Ser-159, respectively) (Fig. 2b). The catalytic base, however, is not conserved between the estrogen sulfotransferase and the heparan sulfotransferases. The heparan sulfotransferases do not contain a residue structurally equivalent to the catalytic histidine found in cytosolic sulfotransferases such as the estrogen sulfotransferases. However, a conserved glutamate is located at a different position in the catalytic sites of NST-1 (Glu-642) and 3-OST-1 (Glu-90) (Fig. 2b). This glutamate residue was proposed to serve as the catalytic base for the activity of NST-1 (33, 34). In both 3-OST-1 and NST-1 structures, this glutamate is found on the inside of the large cleft. Mutation at Glu-90 of 3-OST-1 results in complete loss of sulfotransferase activity as described below, suggesting that Glu-90 is critical for the catalytic function of 3-OST-1.

Heparan Sulfate Binding Site—The large open cleft of the 3-OST-1 structure is believed to be the HS binding site (Fig 3a). This hypothesis is based on the fact that this open cleft in NST-1 has been shown to accommodate a hexasaccharide and provides access to the sulfuryl group of PAPS, where the sulfotransfer reaction occurs (34). Despite the overall fold of these two enzymes being similar, the cleft of 3-OST-1 differs from that of NST-1 in both the primary amino acid sequence and the distribution of the positively charged amino acid residues. NST-1 contains an insertion immediately before the catalytic base (residues Asn-633—Glu-641) that does not exist in 3-OST-1 molecules (Figs. 3b and 4). Mutations from this loop F640A and E641A have a significant effect on NST-1 activity (34). Because these residues are not conserved in the 3-OSTs, it is unlikely that this loop of NST-1 plays a fundamental role in catalysis of all HS sulfotransferase reaction. Therefore, it is possible that this NST-1-specific loop helps the enzyme to recognize NST-1-specific saccharide units within its polysaccharide substrate (the structures of NST-1 and 3-OST-1 substrates are shown in Fig. 1).



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 4.
Alignment of mouse 3-OST-1 with human 3-OST-5, 3-OST-3A, and NST-1. NST-1 alignment is based on the structural alignment with 3-OST-1. Regions with yellow background are structurally dissimilar. Mutants of residues in red, knockout activity in 3-OST-1, <2% WT activity (orange), <10% WT (green), and >10% WT (blue). Residues in purple form a disulfide bond. NST-1 amino acids labeled by a red asterisk indicate amino acid mutants with no activity, and green asterisk-labeled residues have greatly reduced activity (results are taken from Kakuta et al. (34)). The percentage of amino acid identity with 3-OST-1 is shown in the bottom right corner of this figure.

 
The majority of the residues that line this cleft are not conserved. An increase in overall positive charge of the surface of the 3-OST-1 cleft as compared with the NST-1 cleft (Fig. 5) is consistent with the greater number of sulfo groups on the 3-OST-1 substrate than found on the NST-1 substrate (Fig. 1). Interestingly, additional electron density was found in the electron density maps of 3-OST-1 that we have modeled as inorganic sulfate. Residues Arg-72, Lys-123, and Lys-274 are all within hydrogen-bonding distance to the modeled inorganic sulfate (Table II). The position of this modeled inorganic sulfate may represent a sulfo group binding site for the HS substrate, conferring specificity for the 3-OSTs. Consistent with this observation, mutations of Lys-123 and Arg-72 (described below) result in a significant reduction of the sulfotransferase activity (Table III).



View larger version (92K):
[in this window]
[in a new window]
  		FIG. 5.
Charged surface diagram of the proposed heparan binding cleft of the sulfotransferase domains of NST-1 (a) and 3-OST-1 (b). The global position of the cleft is marked with a green dashed line. Blue surfaces signify positive charge, whereas red surfaces signify negative charge. The double-sided dash arrows (in green) indicate the region where HS may bind. This figure was created using Swiss PDB viewer.

 


View this table:
[in this window]
[in a new window]
  		TABLE III
Summary of the analysis of 3-OST-1 mutants

The wild type m3-OST-1 was constructed by replacing N-terminal 47 amino acid residues with a His6 tag to facilitate the protein purification.

 
Mutational Analysis of 3-OST-1—Site-directed mutagenesis experiments were performed to help determine which amino acid residues might be involved in PAPS binding, HS binding, and/or catalysis. Eighteen different amino acid residues within and around the PAPS binding site and the proposed HS binding cleft were mutated. The results of the mutagenesis study are summarized in Table III. The positions of the mutation sites at the active site of 3-OST-1 are shown in Fig. 6. Binding of enzymatically modified HS to AT were compared in those mutants that retained sulfotransferase activity. HS modified by all of these mutants bound to AT, suggesting that these mutant proteins maintain the substrate specificity of 3-OST-1 (data not shown). Point mutations in residues 67, 68, 72, 90, 92, 95, 123, and 276 abolish or significantly reduce the enzymatic activity, suggesting that these residues are essential for sulfotransferase activity.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 6.
Stereo diagram of the heparan binding cleft of 3-OST-1. Residues that have been mutated in this study are shown. Mutations of residues in red abolish activity, whereas mutations of residues in orange reduce the activity to <2% of wild type. Mutations of residues in green reduce the activity to <10% of wild type. Mutations of residues in blue do not significantly affect activity. For this figure the oxygen, nitrogen, and phosphorous atoms are colored red, blue, and magenta, respectively. This figure was created using Molscript (37) and Raster3D (38).

 
To help decipher the specific roles of these individual amino acids in catalysis, binding affinity for PAP was measured and compared with wild type using ITC analysis (Table IV). The use of PAP as an analog for mimicking the interaction between PAPS and sulfotransferases is a widely used approach, provided that the binding affinity of sulfotransferases to PAP is similar to the affinity of sulfotransferase to PAPS (18). Indeed, we determined the KD of 3-OST-1 (WT) for PAP to be 14 µM, very close to the 10 µM Km of wild type 3-OST-1 for PAPS, determined by kinetic analysis (35). Our result suggests that the PAP binding affinity of 3-OST-1 provides a good estimate for the binding affinity to PAPS. The binding affinity (KD values) of the protein to PAP among the mutants K123A, R67E, E90Q, and R72E is similar to the wild type protein, suggesting that residues Arg-67, Arg-72, Glu-90, and Lys-123 are not directly involved in the binding to PAP.2 However, we were unable to accurately determine the KD values for mutants K68A and mutant R276A because the binding affinity is too low. We next compared the binding/elution profiles of these proteins on a PAP-agarose column. We find that the wild type 3-OST-1 protein was eluted from the column at 1 M NaCl, whereas 3-OST-1 K68A and 3-OST-1 R276A were eluted at 600 and 150 mM NaCl, respectively (chromatograms not shown). These results suggest that the PAP binding affinities of 3-OST-1 K68A and 3-OST-1 R276A are indeed significantly reduced. The decrease in the PAP binding affinity of mutant K68A is consistent with our crystal structure data that reveals the side chain of Lys-68 is in position to form a hydrogen bond with the 5'-phosphate of PAP. However, the reason for a decrease in the PAP binding affinity of mutant R276A is unclear since the side chain of this arginine residue points away from both the 3'-phosphate and 5'-phosphate of PAP.


View this table:
[in this window]
[in a new window]
  		TABLE IV
Comparison of the thermodynamic parameters of PAP to 3-OST-1 WT and 3-OST-1 mutants as determined by ITC analysis

 

Among those mutants that have a significant decrease in activity, Glu-90 and Lys-123 of 3-OST-1 are conserved in NST-1 (Glu-642 and Lys-676, respectively) and other 3-OSTs, suggesting that these two residues serve similar functions for the activities of these HS sulfotransferases. As described above, the proposed function of Glu-90 of 3-OST-1 or Glu-642 of NST-1 is to serve as a catalytic base in an SN2-like in-line displacement reaction. Indeed, mutations in Glu-642 of NST-1 and Glu-90 of 3-OST-1 abolished sulfotransferase activity (34). The crystal structure data suggest that Lys-123 in 3-OST-1 is in a position to interact with the sulfo group of PAPS (Fig. 2b). This interaction has also been suggested to occur in NST-1 (Lys-676) based on modeling of PAPS into the active site (33). It is possible that the role of Lys-123 is not to increase binding affinity for PAPS but rather to assist in stabilizing the transition state by interacting with the equatorial oxygen atoms of the sulfo group.

Several amino acid residues critical for the sulfotransferase activity of 3-OST-1 are conserved in other 3-OST isoforms, including 3-OST-1, -2, -3, -4, and -5, but are not conserved in NSTs (36) (Fig. 4). These residues include Arg-67, Arg-72, His-92, and Asp-95.3 This observation suggests that these residues contribute to the substrate specificity of 3-O-sulfotransferases. At the present time, it is unclear how these amino acid residues contribute to the substrate specificity, namely how 3-OST sulfonates the 3-OH position, whereas NST sulfonates the 2-amino position of the glucosamine unit. In addition, a possible catalytic role for residues His-92 and Asp-95 cannot be ruled out. Atom NE2 of His-92 from 3-OST-1 is only 3.3 Å away from a carboxylate oxygen atom of the proposed base Glu-90. Additionally, Asp-95 forms a hydrogen bond with ND1 of His-92. This sequence of residues (Glu-90-His-92-Asp-95) provides for a potential hydrogen-bonding network. Supporting this hypothesis, the mutant D95N, which could geometrically maintain the hydrogen-bonding network, does retain some sulfotransferase activity, whereas the D95A mutant does not (Table III). Interestingly in NST-1, Gln-644 is within hydrogen-bonding distance of Glu-642 (3.1 Å) the proposed base. The mutant Q644A also shows a significant loss of activity, suggesting a similar role to His-92 in 3-OST-1 for catalytic function. This proposed hydrogen bonding network could either provide activation for the glutamate as the base for catalysis or simply play a structural role by orienting the base in the proper conformation for catalysis.

The positions of residues Arg-67 and Arg-72 do not appear to support a role in catalysis. In NST-1, the corresponding residues are Gln-613 and Thr-618, respectively. The positive charge on these arginine residues in 3-OST-1 may assist in the interaction of these residues with negatively charged sulfo groups on the HS substrate. As previously mentioned, Arg-72 lies within hydrogen-bonding distance of the free inorganic sulfate modeled into the electron density. To fully understand the role of these residues and others in 3-OST-1 substrate binding, a ternary complex with both HS and PAP bound to 3-OST-1 will be required.

In conclusion, we have presented the results from the study of a crystal structure of the binary complex of 3-OST-1 and PAP and mutational analysis. Comparing the current structure of 3-OST-1 with the previously published structure of NST-1, several amino acid residues have been identified that may play a role in directing the substrate specificity of HS sulfotransferases. Because 3-OST is present in six different isoforms and the 3-OST-modified HS pose distinct biological activities, a remaining challenge is to understand the mechanism employed by the different isoforms to distinguish the saccharide sequence of their unique substrates. From the present study we are unable to reveal the precise molecular details of the substrate specificity differences between the 3-OSTs. Although the present study does not reveal the mechanism of substrate specificity differences between the 3-OSTs, the results from this study provide valuable structural information toward a comprehensive understanding of HS biosynthesis.


   FOOTNOTES
 
The atomic coordinates and structure factors (code 1S6T [PDB] ) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported in part by National Institutes of Health Grant AI50050 (to J. L.) and American Heart Association Mid-Atlantic Affiliate Grant-in-aid 0355800U (to J. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

** To whom correspondence and reprint requests should be addressed: Rm. 309, Beard Hall, University of North Carolina, Chapel Hill, NC 27599. Tel: 919-843-6511; Fax: 919-843-5432; E-mail: jian_liu{at}unc.edu.

1 The abbreviations used are: HS, heparan sulfate; AT, antithrombin; 3-OST, 3-O-sulfotransferase; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; PAP, 3'-phosphoadenosine 5'-phosphate; PSB, phosphosulfate binding; NST-1, N-deacetylase/N-sulfotransferase; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; ITC, isothermal titration calorimetry; MOPS, 4-morpholinepropanesulfonic acid; WT, wild type. Back

2 We were unable to obtain sufficient amount purified 3-OST-1 H92F, 3-OST-1 D95A, and 3-OST-1 D95N mutants for ITC analyses. However, we purified sufficient amount of the mutant proteins to obtain the elution profiles from PAP-agarose chromatography. Both 3-OST-1 H92F and 3-OST-1 D95N were eluted from the column at 1 M NaCl, suggesting that the mutants have similar binding affinity to PAP as that of wild type protein. Back

3 The corresponding amino acid residue for Arg-67 of 3-OST-1 in 3-OST-2, 3-OST-3, and 3-OST-5 are Lys-113, Lys-136, and Arg-99, respectively. The corresponding amino acid residue for 3-OST-4 is not published. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Ashutosh Tripathy (University of North Carolina, Macromolecular Interaction Facility) for the assistance with isothermal titration calorimetry study, Dr. Joe Krahn for help in structure determination, Dr. Z. Jin of SER-CAT for collection of the data, and Drs. Jeffrey Boyington and Lee G. Pedersen as well as Andrea Moon for critical reading of the manuscript. Use of the Advanced Photon Source was supported by the United States Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract W-31-109-Eng-38.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Esko, J. D., and Selleck, S. B. (2002) Annu. Rev. Biochem. 71, 435-471[CrossRef][Medline] [Order article via Infotrieve]
  2. Rosenberg, R. D., Showrak, N. W., Liu, J., Schwartz, J. J., and Zhang, L. (1997) J. Clin. Investig. 99, 2062-2070[Medline] [Order article via Infotrieve]
  3. Liu, J., and Thorp, S. C. (2002) Med. Res. Rev. 22, 1-25[CrossRef][Medline] [Order article via Infotrieve]
  4. Lindahl, U., Kusche-Gullberg, M., and Kjellen, L. (1998) J. Biol. Chem. 273, 24979-24982[Free Full Text]
  5. Kuberan, B., Lech, M. Z., Beeler, D. L., Wu, Z. L., and Rosenberg, R. D. (2003) Nat. Biotechnol. 21, 1343-1346[CrossRef][Medline] [Order article via Infotrieve]
  6. Atha, D. H., Lormeau, J.-C., Petitou, M., Rosenberg, R. D., and Choay, J. (1985) Biochemistry 24, 6723-6729[CrossRef][Medline] [Order article via Infotrieve]
  7. Dewerchin, M., Herault, J.-P., Wallays, G., Petitou, M., Schaeffer, P., Millet, L., Weitz, J. I., Moons, L., Collen, D., Carmeliet, P., and Herbert, J.-M. (2003) Cir. Res. 93, 1120-1126[Abstract/Free Full Text]
  8. Koide, T., Odani, S., Takahashi, K., Ono, T., and Sakuragawa, N. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 289-293[Abstract/Free Full Text]
  9. van Boven, H. H., and Lane, D. A. (1997) Semin. Hematol. 34, 188-204[Medline] [Order article via Infotrieve]
  10. Boyer, C., Wolf, M., Vedrenne, J., Meyer, D., and Larrieu, M. J. (1986) Thromb. Haemostasis 56, 18-22[Medline] [Order article via Infotrieve]
  11. Weitz, J. I. (2003) J. Clin. Investig. 111, 952-954[CrossRef][Medline] [Order article via Infotrieve]
  12. Liu, J., Shworak, N. W., Fritze, L. M. S., Edelberg, J. M., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27072-27082[Abstract/Free Full Text]
  13. Duncan, M. B., Chen, J., Krise, J. P., and Liu, J. (2004) Biochim. Biophys. Acta 1671, 34-43[Medline] [Order article via Infotrieve]
  14. HajMohammadi, S., Enjyoji, K., Princivalle, M., Christi, P., Lech, M., Beeler, D. L., Rayburn, H., Schwartz, J. J., Barzegar, S., de Agostini, A. I., Post, M. J., Rosenberg, R. D., and Shworak, N. W. (2003) J. Clin. Investig. 111, 989-999[CrossRef][Medline] [Order article via Infotrieve]
  15. Liu, J., and Rosenberg, R. D. (2002) in Handbook of Glycosyltransferases and Their Related Genes (Taniguchi, N., and Fukuda, M., eds) pp. 475-483, Springer-Verlag, Tokyo
  16. Xia, G., Chen, J., Tiwari, V., Ju, W., Li, J.-P., Malmström, A., Shukla, D., and Liu, J. (2002) J. Biol. Chem. 277, 37912-37919[Abstract/Free Full Text]
  17. Shukla, D., Liu, J., Blaiklock, P., Shworak, N. W., Bai, X., Esko, J. D., Cohen, G. H., Eisenberg, R. J., Rosenberg, R. D., and Spear, P. G. (1999) Cell 99, 13-22[CrossRef][Medline] [Order article via Infotrieve]
  18. Negishi, M., Pedersen, L. G., Petrotchenko, E., Shevtsov, S., Gorokhov, A., Kakuta, Y., and Pedersen, L. C. (2001) Arch. Biochem. Biophys. 390, 149-157[CrossRef][Medline] [Order article via Infotrieve]
  19. Grunwell, J. R., and Bertozzi, C. R. (2002) Biochemistry 41, 13117-13126[CrossRef][Medline] [Order article via Infotrieve]
  20. Kakuta, Y., Pedersen, L. G., Carter, C. W., Negishi, M., and Pedersen, L. C. (1997) Nat. Struct. Biol. 4, 904-908[CrossRef][Medline] [Order article via Infotrieve]
  21. Kakuta, Y., Sueyoshi, T., Negishi, M., and Pedersen, L. C. (1999) J. Biol. Chem. 274, 10673-10676[Abstract/Free Full Text]
  22. Kakuta, Y., Petrotchenko, E. V., Pedersen, L. C., and Negishi, M. (1998) J. Biol. Chem. 273, 27325-27330[Abstract/Free Full Text]
  23. Lee, K. A., Fuda, H., Lee, Y. C., Negishi, M., Strott, C. A., and Pedersen, L. C. (2003) J. Biol. Chem. 278, 44593-44599[Abstract/Free Full Text]
  24. Pedersen, L. C., Petrotchenko, E., Shevtsov, S., and Negishi, M. (2002) J. Biol. Chem. 277, 17928-17932[Abstract/Free Full Text]
  25. Shworak, N. W., Liu, J., Fritze, L. M. S., Schwartz, J. J., Zhang, L., Logeart, D., and Rosenberg, R. D. (1997) J. Biol. Chem. 272, 28008-28019[Abstract/Free Full Text]
  26. Bame, K. J., and Esko, J. D. (1989) J. Biol. Chem. 264, 8059-8065[Abstract/Free Full Text]
  27. Otwinowski, Z., and Minor, V. (1997) Methods Enzymol. 276, 307-326
  28. Bailey, S. (1994) Acta Crystallogr. Sect. D 50, 760-763[CrossRef][Medline] [Order article via Infotrieve]
  29. Vagin, A., and Teplyakov, A. (1997) J. Appl. Crystallogr. 30, 1022-1025[CrossRef]
  30. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
  31. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110-119
  32. Matthews, B. W. (1968) J. Mol. Biol. 33, 491-497[Medline] [Order article via Infotrieve]
  33. Gorokhov, A., Perera, L., Darden, T. A., Negishi, M., Pedersen, L. C., and Pedersen, L. G. (2000) Biophys. J. 79, 2909-2917[Abstract/Free Full Text]
  34. Kakuta, Y., Li, L., Pedersen, L. C., Pedersen, L. G., and Negishi, M. (2003) Biochem. Soc. Trans. 31, 331-334[Medline] [Order article via Infotrieve]
  35. Myette, J. R., Shriver, Z., Liu, J., Venkataraman, G., Rosenberg, R., and Sasisekharan, R. (2002) Biochem. Biophys. Res. Commun. 290, 1206-1213[CrossRef][Medline] [Order article via Infotrieve]
  36. Shworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. A., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 5170-5184[Abstract/Free Full Text]
  37. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
  38. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524[Medline] [Order article via Infotrieve]
  39. Chen, J., Duncan, M. B., Carrick, K., Pope, M., and Liu, J. (2003) Glycobiology 13, 785-794[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
D. Xu, D. Song, L. C. Pedersen, and J. Liu
Mutational Study of Heparan Sulfate 2-O-Sulfotransferase and Chondroitin Sulfate 2-O-Sulfotransferase
J. Biol. Chem., March 16, 2007; 282(11): 8356 - 8367.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Chen, F. Y. Avci, E. M. Munoz, L. M. McDowell, M. Chen, L. C. Pedersen, L. Zhang, R. J. Linhardt, and J. Liu
Enzymatic Redesigning of Biologically Active Heparan Sulfate
J. Biol. Chem., December 30, 2005; 280(52): 42817 - 42825.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
L. Chen, K. Ichihara-Tanaka, and T. Muramatsu
Role of the Carboxyl-Terminal Region in the Activity of N-Acetylglucosamine 6-O-Sulfotransferase-1
J. Biochem., November 1, 2004; 136(5): 659 - 664.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. F. Moon, S. C. Edavettal, J. M. Krahn, E. M. Munoz, M. Negishi, R. J. Linhardt, J. Liu, and L. C. Pedersen
Structural Analysis of the Sulfotransferase (3-O-Sulfotransferase Isoform 3) Involved in the Biosynthesis of an Entry Receptor for Herpes Simplex Virus 1
J. Biol. Chem., October 22, 2004; 279(43): 45185 - 45193.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E. M. Munoz and R. J. Linhardt
Heparin-Binding Domains in Vascular Biology
Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1549 - 1557.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/24/25789    most recent
M401089200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend